NEW YORK (GenomeWeb) – Danaher today said that its first quarter sales grew 5 percent year over year, while its Life Science & Diagnostics segment grew 2 percent. 

For the three months ended April 3, the Washington-based conglomerate posted sales of $4.87 billion, up from $4.66 billion in the year-ago quarter, and beating the consensus Wall Street estimate of $4.83 billion. 

Core sales improved 5 percent year over year, while acquisitions added 6 percentage points to growth. Currency effects dampened results by 6.5 percent, the firm said. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.